**
Patients battling cancer in England face significant barriers to accessing advanced radiotherapy techniques, a situation described by medical professionals as a “deadly postcode lottery.” Despite the existence of effective treatment options, many patients are left behind due to bureaucratic obstacles and funding issues within the NHS.
A Growing Concern for Cancer Patients
The Royal College of Radiologists (RCR) and Radiotherapy UK are urging Health Secretary Wes Streeting to address the limitations imposed by NHS England that restrict the availability of two promising radiotherapy treatments: stereotactic ablative body radiotherapy (SABR) and molecular radiotherapy (MRT). These therapies are already widely accessible in other nations, but in England, their use is hampered by complex funding and commissioning processes.
Dr Nicky Thorp, RCR’s vice-president for clinical oncology, highlighted the frustration felt by healthcare professionals: “A number of innovative cancer treatments exist and are known by cancer doctors to be effective, but they are in only limited use in the NHS in England.” The result is that patients may miss out on treatments that could potentially reduce the number of sessions needed and lessen side effects.
The Impact of Bureaucracy on Treatment Availability
Current NHS policies mean that only half of cancer treatment centres in England can provide surface-guided radiation therapy (SGRT), a technique that enhances treatment precision through real-time imaging. Facilities that do offer this technology often rely on charitable donations or local funding, as the NHS does not allocate the necessary £250,000 for equipment procurement.
Pat Price, chair of Radiotherapy UK and an oncology professor at Imperial College London, lamented the situation, stating, “The big tragedy of the UK’s poor cancer survival rates is that we know how to fix them but bureaucracy and broken funding systems keep us from making progress.” She pointed out that while SABR is used effectively for lung cancer, other cancer types, such as liver, prostate, and kidney cancers, remain under-treated in the NHS.
Call for Change in Cancer Treatment Funding
The RCR and Radiotherapy UK have called for a re-evaluation of the NHS’s funding mechanisms, particularly the outdated tariff system that discourages the use of innovative therapies. Price noted that hospitals are compensated for traditional radiotherapy treatments but are not financially supported for newer, more effective options. This disparity leads to limited access for patients who could benefit from these advanced therapies.
Dr Thorp added, “The rollout of SABR to treat cancer has been slow. It is still used for fewer types of cancer than it could be, as evidence shows it is effective for more cancers than it is used for.” Cancer Research UK has also expressed concern regarding treatment inequalities, which have contributed to the UK’s lagging cancer survival rates compared to other countries.
NHS Response and Future Prospects
NHS England has stated that the forthcoming cancer plan aims to enhance access to novel treatments. A spokesperson affirmed, “Every NHS trust in England delivering radiotherapy is already able to offer stereotactic ablative radiotherapy, and it is available for patients where there is strong clinical evidence that it is appropriate.” The organisation is working closely with the RCR and other stakeholders to enable consistent access to proven radiotherapy innovations.
Why it Matters
The disparity in access to cancer treatments within the NHS raises serious ethical and health concerns. As the healthcare community calls for action to eliminate bureaucratic barriers, the implications for patient outcomes are profound. Improving access to innovative therapies could enhance survival rates, reduce waiting times, and ultimately transform the experience of countless individuals facing cancer in England. The time for change is now, as every patient deserves equal access to the best possible care, regardless of their postcode.
